Tyme Technologies Inc
NASDAQ:TYME
Intrinsic Value
Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of TYME.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Tyme Technologies Inc's business.
What risks and challenges
does Tyme Technologies Inc face in the near future?
Summarize the latest earnings report
of Tyme Technologies Inc.
Provide P/E
for Tyme Technologies Inc and its competitors.
Balance Sheet Decomposition
Tyme Technologies Inc
Current Assets | 79m |
Cash & Short-Term Investments | 77.1m |
Other Current Assets | 1.9m |
Non-Current Assets | 1.1m |
Long-Term Investments | 1.1m |
PP&E | 28.2k |
Current Liabilities | 5.6m |
Accrued Liabilities | 491.6k |
Other Current Liabilities | 5.1m |
Non-Current Liabilities | 400.9k |
Other Non-Current Liabilities | 400.9k |
Earnings Waterfall
Tyme Technologies Inc
Revenue
|
0
USD
|
Operating Expenses
|
-25.5m
USD
|
Operating Income
|
-25.5m
USD
|
Other Expenses
|
1.3m
USD
|
Net Income
|
-24.2m
USD
|
Free Cash Flow Analysis
Tyme Technologies Inc
What is Free Cash Flow?
TYME Profitability Score
Profitability Due Diligence
Tyme Technologies Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Tyme Technologies Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
TYME Solvency Score
Solvency Due Diligence
Tyme Technologies Inc's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Score
Tyme Technologies Inc's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TYME Price Targets Summary
Tyme Technologies Inc
Ownership
TYME Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
TYME Price
Tyme Technologies Inc
Average Annual Return | -12.48% |
Standard Deviation of Annual Returns | 9.68% |
Max Drawdown | -94% |
Market Capitalization | 53.5m USD |
Shares Outstanding | 172 207 008 |
Percentage of Shares Shorted | 0.59% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. The company is headquartered in Bedminster, New Jersey and currently employs 17 full-time employees. The company went IPO on 2012-05-25. The firm is focused on developing cancer metabolism-based therapies (CMBTs) for a range of solid tumors and hematologic cancers. The firm's lead clinical CMBT compound, SM-88, is an oral investigational modified tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cell's key defenses and leading to cell death through oxidative stress and exposure to the body's natural immune system. The company is also developing SM-88i, an injectable formulation of SM-88 for the treatment of multiple oncology indications. Its TYME-18, is a pre-clinical CMBT designed for the intra-tumoral delivery of the treatment and increase the permeability of cancer cells, while delivering a therapy having selective cytotoxic effect on the tumor. Its TYME-19, is an oral, synthetically produced member of the bile acid family that is being developed for the potential treatment of COVID-19.